Charles River (CRL) and Toxys announced a collaboration that offers Charles River’s clients access to ReproTracker, a human stem cell-based in vitro assay that rapidly and reliably identifies developmental toxicity hazards of new drugs and chemicals.
Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CRL:
- Charles River upgraded to Outperform from Market Perform at William Blair
- Charles River price target raised to $200 from $190 at Evercore ISI
- Nike upgraded, RH downgraded: Wall Street’s top analyst calls
- Charles River upgraded to Overweight from Equal Weight at Barclays
- Charles River Labs: Navigating Leadership Changes and Market Challenges with a Hold Rating